Neerincx A - Search Results

1

Utilizing TAPBPR to promote exogenous peptide loading onto cell surface MHC I molecules.

Ilca FT, Neerincx A, Wills MR, de la Roche M, Boyle LH. Ilca FT, et al. Among authors: neerincx a. Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):E9353-E9361. doi: 10.1073/pnas.1809465115. Epub 2018 Sep 13. Proc Natl Acad Sci U S A. 2018. PMID: 30213851 Free PMC article.

2

TAPBPR alters MHC class I peptide presentation by functioning as a peptide exchange catalyst.

Hermann C, van Hateren A, Trautwein N, Neerincx A, Duriez PJ, Stevanović S, Trowsdale J, Deane JE, Elliott T, Boyle LH. Hermann C, et al. Among authors: neerincx a. Elife. 2015 Oct 6;4:e09617. doi: 10.7554/eLife.09617. Elife. 2015. PMID: 26439010 Free PMC article.

3

TAPBPR mediates peptide dissociation from MHC class I using a leucine lever.

Ilca FT, Neerincx A, Hermann C, Marcu A, Stevanović S, Deane JE, Boyle LH. Ilca FT, et al. Among authors: neerincx a. Elife. 2018 Nov 28;7:e40126. doi: 10.7554/eLife.40126. Elife. 2018. PMID: 30484775 Free PMC article.

4

Properties of the tapasin homologue TAPBPR.

Neerincx A, Boyle LH. Neerincx A, et al. Curr Opin Immunol. 2017 Jun;46:97-102. doi: 10.1016/j.coi.2017.04.008. Epub 2017 May 18. Curr Opin Immunol. 2017. PMID: 28528220 Review.

5

Preferential interaction of MHC class I with TAPBPR in the absence of glycosylation.

Neerincx A, Boyle LH. Neerincx A, et al. Mol Immunol. 2019 Sep;113:58-66. doi: 10.1016/j.molimm.2018.06.269. Epub 2018 Aug 1. Mol Immunol. 2019. PMID: 30077416 Free PMC article.

6

Response to Letter to The Editor on article "Preferential interaction of MHC class I with TAPBPR in the absence of glycosylation".

Neerincx A, Boyle LH. Neerincx A, et al. Mol Immunol. 2019 Oct;114:663. doi: 10.1016/j.molimm.2019.05.003. Epub 2019 Sep 11. Mol Immunol. 2019. PMID: 31521384 No abstract available.

7

TAPBPR bridges UDP-glucose:glycoprotein glucosyltransferase 1 onto MHC class I to provide quality control in the antigen presentation pathway.

Neerincx A, Hermann C, Antrobus R, van Hateren A, Cao H, Trautwein N, Stevanović S, Elliott T, Deane JE, Boyle LH. Neerincx A, et al. Elife. 2017 Apr 20;6:e23049. doi: 10.7554/eLife.23049. Elife. 2017. PMID: 28425917 Free PMC article.

8

Sialic acid-binding immunoglobulin-like lectin (Sigelac)-15 is a rapidly internalised cell-surface antigen expressed by acute myeloid leukaemia cells.

Cao H, Neerincx A, de Bono B, Lakner U, Huntington C, Elvin J, Gudgin E, Pridans C, Vickers MA, Huntly B, Trowsdale J, Barrow AD. Cao H, et al. Among authors: neerincx a. Br J Haematol. 2021 Jun;193(5):946-950. doi: 10.1111/bjh.17496. Epub 2021 May 5. Br J Haematol. 2021. PMID: 33951750 Clinical Trial.

9

The N-terminal domain of NLRC5 confers transcriptional activity for MHC class I and II gene expression.

Neerincx A, Jakobshagen K, Utermöhlen O, Büning H, Steimle V, Kufer TA. Neerincx A, et al. J Immunol. 2014 Sep 15;193(6):3090-100. doi: 10.4049/jimmunol.1401065. Epub 2014 Aug 15. J Immunol. 2014. PMID: 25127861

10

NLRC5 controls basal MHC class I gene expression in an MHC enhanceosome-dependent manner.

Neerincx A, Rodriguez GM, Steimle V, Kufer TA. Neerincx A, et al. J Immunol. 2012 May 15;188(10):4940-50. doi: 10.4049/jimmunol.1103136. Epub 2012 Apr 6. J Immunol. 2012. PMID: 22490867

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

59 results

Search Page

Filters